Stay updated on Phase II Pembrolizumab Plus GVD Clinical Trial
Sign up to get notified when there's something new on the Phase II Pembrolizumab Plus GVD Clinical Trial page.

Latest updates to the Phase II Pembrolizumab Plus GVD Clinical Trial page
- CheckyesterdayChange DetectedThe study record page shows a revision label updated from v3.5.3 to v3.5.4, indicating a small update to the page’s metadata. This change does not alter the study details or user-facing content.SummaryDifference0.0%

- Check8 days agoChange DetectedNew bibliographic entries were added to the Publications section, including a 2026 article on checkpoint inhibitors in Hodgkin lymphoma, and a note that PubMed entries may be auto-filled from PubMed.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedA minor update to the ClinicalTrials.gov page’s displayed software/version revision number (from v3.5.2 to v3.5.3) occurred, without any visible change to the trial’s study details.SummaryDifference0.0%

- Check29 days agoChange DetectedAdded updated contact details for study staff (e.g., Matthew Mei, MD; Ranjana Advani, MD) and new location information for Stanford University Medical Center and City of Hope Cancer Center, and revised total study locations from 8 to 10.SummaryDifference0.9%

- Check59 days agoChange DetectedRevision: v3.5.0 was added. This change is a metadata/versioning update and does not alter the study details or how users interact with the page.SummaryDifference0.0%

- Check66 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

Stay in the know with updates to Phase II Pembrolizumab Plus GVD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Pembrolizumab Plus GVD Clinical Trial page.